USA flag logo/image

An Official Website of the United States Government

Nanocrystal Delivery of Hydrophobic Anticancer Drugs

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2010 / STTR
Agency Tracking Number:
R41EB013482
Solicitation Year:
2010
Solicitation Topic Code:
NIBIB
Solicitation Number:
PA09-081
Small Business Information
PDS BIOTECHNOLOGY CORPORATION
500 Industrial Drive Lawrenceburg, IN 47025-2971
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Nanocrystal Delivery of Hydrophobic Anticancer Drugs
Agency: HHS
Contract: 1R41EB013482-01A1
Award Amount: $174,273.00
 

Abstract:

DESCRIPTION (provided by applicant): Nanosystems have been extensively investigated for drug delivery; however, there is a challenge in transferring nanotechnology from research laboratories into pharmaceutical industry. The scientific basis for this proposal originated from our three-phase nanoparticle engineering (3PNE) method recently developed which includes phase 1, amorphous precipitate; phase 2, hydrated amorphous aggregate; and phase 3, stabilized nanocrystals (NCs). The 3PNE has been applied to the development of nanocrystals for the effective delivery of the anticancer drug, Paclitaxel (PTX). This nanocrystal is unique in its simplicity, low toxicity and its high drug loading ratio. The goal of this application is to further explore this novel nanotechnology and its feasibility for commercialization for intravenous PTX delivery. To achieve this goal, the following aims are proposed. Aim 1: Develop a technology to pave the way for large scale production of PTX nanocrystals. Aim 2: Characterize thePTX nanocrystals for their pharmaceutical kinetics, bio-distribution and acute toxicity in animals. Aim 3: Establish targeted PTX nanocrystals to further increase the anti-tumor efficiency. We believe that the success of this project will accelerate the commercialization of this nanotechnology for cancer therapy. PUBLIC HEALTH RELEVANCE: Paclitaxel nanocrystals developed using the novel three-phase nanoparticle engineering (3PNE) technology have significant potential for commercialization due to their simplicity, low toxicity, and cost effectiveness. The technology lowers drug dosing and improves efficacy.

Principal Investigator:

Frank Bedu-addo
513-755-3065
fbeduaddo@pdsbiotech.com

Business Contact:

Frank B. Addo
812-537-0779
fbeduaddo@pdsbiotech.com
Small Business Information at Submission:

PDS BIOTECHNOLOGY CORPORATION
500 Industrial Drive Lawrenceburg, IN 47025-2971

EIN/Tax ID: 120403151
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
University Of North Carolina Chapel Hill
Office Of Sponsored Research
CHAPEL HILL, NC 27599-
Contact: